| Market Cap | 2.77M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -478k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 75.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 87.00% |
| Dividend | N/A | Price/Book | 0.74 | EPS next 5Y | - | 52W High Chg | -7.00% |
| Recommedations | - | Quick Ratio | 20.08 | Shares Outstanding | 9.88M | 52W Low Chg | 155.00% |
| Insider Own | - | ROA | -7.67% | Shares Float | 4.81M | Beta | -1.76 |
| Inst Own | - | ROE | -12.00% | Shares Shorted/Prior | -/48.54K | Price | 0.28 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 1,525 | Target Price | - |
| Oper. Margin | - | Earnings Date | Jan 14 | Volume | 35,018 | Change | 0.00% |
Tikcro Technologies Ltd. focuses on development of biotechnology project in Israel. It offers anti-cytotoxic T-lymphocyte-associated protein 4 for cancer immune treatment. The company was formerly known as Tioga Technologies Ltd. and changed its name to Tikcro Technologies Ltd. in September 2003. Tikcro Technologies Ltd. was founded in 1999 and is headquartered in Hadera, Israel.
